Thinly traded micro cap Marker Therapeutics (NASDAQ:MRKR) is up 8% premarket on average volume in reaction to its announcement that
the FDA has lifted the clinical hold on its planned clinical trial
evaluating its MultiTAA T cell therapy in patients with post-transplant
acute myeloid leukemia (AML).
The agency instituted the clinical hold in
November 2019 citing the need for additional information and technical
specifications for two legacy reagents supplied by third parties used in
the manufacturing process.
https://seekingalpha.com/news/3540507-marker-up-8-premarket-on-removal-of-clinical-hold-on-cell-therapy-study
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.